Turnstone Biologics Stock (NASDAQ:TSBX)

Ownership Financials Chart

Previous Close

$0.36

52W Range

$0.29 - $3.05

50D Avg

$0.35

200D Avg

$0.46

Market Cap

$8.25M

Avg Vol (3M)

$265.75K

Beta

1.19

Div Yield

-

TSBX Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jul 21, 2023

Website

TSBX Performance

TSBX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$19.31M	$73.30M	$101.29M
Operating Income	$-59.03M	$-31.63M	$32.99M
Net Income	$-55.20M	$-30.83M	$33.27M
EBITDA	$-59.03M	$-27.73M	$34.38M
Basic EPS	-	$-1.39	$1.50
Diluted EPS	-	$-1.39	$1.50

Fiscal year ends in Dec 23 | Currency in USD